Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Croley

Psychiatry Lexington, KY Medical Doctor

NPI 1265559272 CMS profile 284734

3050 Harrodsburg Rd, Suite 203, Lexington, KY 40513

Open in the dashboard

General payments

$150,701

468 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Croley of Lexington, KY is reported in the CMS Open Payments database as having received $150,701 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,361 78
2024 General $20,891 71
2023 General $14,573 50
2022 General $17,923 47
2021 General $25,312 60
2020 General $15,796 72
2019 General $15,846 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Croley
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Steven Croley were reported at $40,361. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Steven Croley Psychiatry median Middle half National median
2019 $15,846 $184 $59–$605 $163
2020 $15,796 $119 $36–$372 $114
2021 $25,312 $143 $43–$576 $132
2022 $17,923 $153 $50–$590 $149
2023 $14,573 $170 $56–$651 $160
2024 $20,891 $179 $57–$673 $164
2025 $40,361 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $106,239 219 payments
  2. Ironshore Pharmaceuticals Inc. $36,344 87 payments
  3. Allergan Inc. $5,871 50 payments
  4. Janssen Pharmaceuticals, Inc $535 16 payments
  5. Corium, Inc. $310 18 payments
  6. Tris Pharma Inc $249 18 payments
  7. Neurocrine Biosciences, Inc. $236 8 payments
  8. Sunovion Pharmaceuticals Inc. $220 11 payments
  9. Otsuka America Pharmaceutical, Inc. $108 7 payments
  10. Neuronetics, Inc. $95 3 payments
  11. Other $496 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $90,693 64 payments
  2. Honoraria $34,200 16 payments
  3. Travel and Lodging $18,393 71 payments
  4. Food and Beverage $7,409 316 payments
  5. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Qelbree Viloxazine Hydrochloride $60,875 130 payments
  2. QELBREE Psychology $42,916 85 payments
  3. JORNAY PM Central Nervous Stimulant ADHD $18,375 38 payments
  4. Jornay PM 20mg capsules (Bottle of 100) $14,833 30 payments
  5. VRAYLAR $5,871 50 payments
  6. JORNAY PM Central Nervous System Stimulant $3,136 19 payments
  7. SPRAVATO $344 9 payments
  8. Azstarys $310 18 payments
  9. LATUDA $220 11 payments
  10. INVEGA SUSTENNA $200 8 payments
  11. Other $1,316 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

4,642

Median for Psychiatry & Neurology: 100

Drug cost

$333,954

Median for Psychiatry & Neurology: $2,986

Branded share of claims

17.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 26 $88,735
Aripiprazole Generic 319 $50,916
Vraylar Cariprazine Hcl Brand 34 $47,470
Quetiapine Fumarate Er Quetiapine Fumarate Brand 58 $17,828
Ziprasidone Hcl Generic 60 $10,163
Divalproex Sodium Er Divalproex Sodium Brand 71 $9,855
Lurasidone Hcl Generic 31 $8,944
Trintellix Vortioxetine Hydrobromide Brand 18 $8,585
Paliperidone Er Paliperidone Brand 43 $7,268
Oxcarbazepine Generic 101 $5,831

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $20,690
$20,690 — —
Azstarys
  • Corium, Inc. $118
$118 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $36
$36 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $18
$18 26 —
INGREZZA
  • Neurocrine Biosciences, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record